Showing results (11-20 of 76) with videos related to
Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|June 15, 2018
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitorsEdward Hammond, Nicole M Haynes, Carleen Cullinane, et al.Reviews on Recent Clinical Trials|May 14, 2008
Dendritic cell immunotherapy for melanomaJudy C Peng, Ranjeny Thomas, Keith DredgeCurrent Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Angiogenesis inhibitors in cancer therapyKeith Dredge, Angus G Dalgleish, J Blake MarriottExpert Opinion on Biological Therapy|January 9, 2003
Recent developments in antiangiogenic therapyKeith Dredge, Angus G Dalgleish, J Blake MarriottCritical Reviews in Immunology|June 14, 2003
Immunological effects of thalidomide and its chemical and functional analogsKeith Dredge, J Blake Marriott, Angus G DalgleishAnti-Cancer Drugs|June 5, 2003
Thalidomide analogs as emerging anti-cancer drugsKeith Dredge, Angus G Dalgleish, J Blake MarriottCurrent Drug Targets. Immune, Endocrine and Metabolic Disorders|July 23, 2003
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agentsJ Blake Marriott, Keith Dredge, Angus G DalgleishBritish Journal of Cancer|March 14, 2018
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumoursKeith Dredge, Todd V Brennan, Edward Hammond, et al.Oncotarget|October 15, 2019
Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineDeok-Beom Jung, Miyong Yun, Eun-Ok Kim, et al.Oncotarget|February 12, 2015
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineDeok-Beom Jung, Miyong Yun, Eun-Ok Kim, et al.Pageof 8